DLD Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

DLD Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-446,900	Closed	-$7.23M	–	90
2016 Q4	$7.23M	Buy	+446,900	New	+$8.1M	2.37%	10

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

DLD Asset Management's HZNP Position: Q2 2023 in Review

DLD Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 166,300 shares — an estimated $18.1M sold.

DLD Asset Management first reported a position in HZNP in Q4 2016 and held it in 3 quarters. The position peaked at $18.2M in Q4 2022. 517 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

DLD Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
DLD Asset Management sold 166,300 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $18.1M.
DLD Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 3 quarters.
DLD Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $18.2M in Q4 2022.
517 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on DLD Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.